"10.1371_journal.pone.0139438","plos one","2015-10-01T00:00:00Z","Joanna Mangana; Phil F Cheng; Katja Schindler; Benjamin Weide; Ulrike Held; Anna L Frauchiger; Emanuella Romano; Katharina C Kähler; Sima Rozati; Markus Rechsteiner; Holger Moch; Olivier Michielin; Claus Garbe; Axel Hauschild; Christoph Hoeller; Reinhard Dummer; Simone M Goldinger","Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Department of Dermatology, Medical University of Vienna, Vienna, Austria; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany; Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland; Department of Oncology CHUV Lausanne, Lausanne, Switzerland; Department of Dermatology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany; Department of Dermatology, Stanford University School of Medicine, Stanford, United States of America; Horten Centre for Patient Oriented Research and Knowledge Transfer, University Hospital Zurich, Zurich, Switzerland","Conceived and designed the experiments: RD SMG. Analyzed the data: JM SMG RD UH. Contributed reagents/materials/analysis tools: JM SMG SR ALF HM MR PC BW CG KS CH ER OM KK AH RD. Wrote the paper: JM SMG.","O.M. has a consultant or advisory board relationship with Novartis, Merck Sharp & Dhome, Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Amgen. J.M., P.F.C., K.S, U.H., A.F., E.R., M.R., and H.M. did not declare any conflicts of interest or funding. B.W. received research funding, travel grants, and honoraria from Bristol-Myers Squibb, and travel grants and honoraria from Roche. K.C.K. declares speakers fees and travel grants from BMS, Roche, and MSD. S.R. declares a compensated research fellowship. C.G. reports grants and personal fees from BMS, during the conduct of the study; grants and personal fees from GSK; personal fees from MSD, personal fees from Novartis; grants and personal fees from Roche; personal fees from Philogen; and personal fees from Amgen, outside the submitted work. A.H. reports consultancies for Amgen, BMS, Celgene, Eisai, GSK, MedImmune, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, and Roche Pharma. He receives honoraria from Amgen, BMS, Celgene, Eisai, GSK, MedImmune, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche Pharma and receives trial grants (clinical trials) from Amgen, BMS, Celgene, Eisai, GSK, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, and Roche Pharma. C.H. reports advisory positions at BMS, Roche, GSK and speakers honoraria at BMS, Roche, GSK, MSD, Amgen, and Novartis. R.D. receives research funding from Astra Zeneca, Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Bayer, and has a consultant or advisory board relationship with Astra Zeneca, Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Genta, Bayer, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Spirig, and Amgen. S.M.G. receives research funding from the University Hospital Zurich, has advisory board relationship with Merck Sharp & Dhome and received travel grant support from MSD and BMS. There are no patents, products in development, or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","10","Joanna Mangana","JM",17,TRUE,2,NA,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
